These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

606 related items for PubMed ID: 16130613

  • 21. Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models.
    Dube A, Singh N, Sundar S, Singh N.
    Parasitol Res; 2005 Jun; 96(4):216-23. PubMed ID: 15868188
    [Abstract] [Full Text] [Related]

  • 22. Drug combinations for visceral leishmaniasis.
    Olliaro PL.
    Curr Opin Infect Dis; 2010 Dec; 23(6):595-602. PubMed ID: 20871400
    [Abstract] [Full Text] [Related]

  • 23. In vitro susceptibility of field isolates of Leishmania donovani to Miltefosine and amphotericin B: correlation with sodium antimony gluconate susceptibility and implications for treatment in areas of endemicity.
    Kumar D, Kulshrestha A, Singh R, Salotra P.
    Antimicrob Agents Chemother; 2009 Feb; 53(2):835-8. PubMed ID: 19015344
    [Abstract] [Full Text] [Related]

  • 24. Visceral leishmaniasis (kala-azar)--the Bihar (India) perspective.
    Sinha PK, Ranjan A, Singh VP, Das VN, Pandey K, Kumar N, Verma N, Lal CS, Sur D, Manna B, Bhattacharya SK.
    J Infect; 2006 Jul; 53(1):60-4. PubMed ID: 16269185
    [Abstract] [Full Text] [Related]

  • 25. Observations on the effect of verapamil with sodium stibogluconate in kala azar.
    Thakur CP, Kumar M.
    Trop Geogr Med; 1992 Jan; 44(1-2):15-8. PubMed ID: 1323160
    [Abstract] [Full Text] [Related]

  • 26. Ketoconazole in antimonial unresponsive cases of Kala-azar.
    Jha TK, Singh NK, Jha S.
    J Assoc Physicians India; 1995 May; 43(5):347. PubMed ID: 9081966
    [No Abstract] [Full Text] [Related]

  • 27. In vitro and in vivo interactions between miltefosine and other antileishmanial drugs.
    Seifert K, Croft SL.
    Antimicrob Agents Chemother; 2006 Jan; 50(1):73-9. PubMed ID: 16377670
    [Abstract] [Full Text] [Related]

  • 28. Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its continued use as a first-line drug? An observational study of 80 cases.
    Thakur CP, Sinha GP, Pandey AK, Kumar N, Kumar P, Hassan SM, Narain S, Roy RK.
    Ann Trop Med Parasitol; 1998 Jul; 92(5):561-9. PubMed ID: 9797829
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis.
    Das VN, Pandey K, Verma N, Lal CS, Bimal S, Topno RK, Singh D, Siddiqui NA, Verma RB, Das P.
    Am J Trop Med Hyg; 2009 Mar; 80(3):336-8. PubMed ID: 19270277
    [Abstract] [Full Text] [Related]

  • 31. Cure of antimony-unresponsive Indian post-kala-azar dermal leishmaniasis with oral miltefosine.
    Sundar S, Kumar K, Chakravarty J, Agrawal D, Agrawal S, Chhabra A, Singh V.
    Trans R Soc Trop Med Hyg; 2006 Jul; 100(7):698-700. PubMed ID: 16325873
    [Abstract] [Full Text] [Related]

  • 32. Evaluation of amphotericin B as a first line drug in comparison to sodium stibogluconate in the treatment of fresh cases of kala-azar.
    Thakur CP, Sinha GP, Sharma V, Pandey AK, Kumar M, Verma BB.
    Indian J Med Res; 1993 Jul; 97():170-5. PubMed ID: 8406644
    [Abstract] [Full Text] [Related]

  • 33. [Treatment of visceral leishmaniasis in children].
    Minodier P, Noël G, Blanc P, Uters M, Retornaz K, Garnier JM.
    Med Trop (Mars); 2007 Feb; 67(1):73-8. PubMed ID: 17506279
    [Abstract] [Full Text] [Related]

  • 34. A thirty day course of sodium stibogluconate for treatment of Kala-azar in Nepal.
    Karki P, Koirala S, Parija SC, Hansdak SG, Das ML.
    Southeast Asian J Trop Med Public Health; 1998 Mar; 29(1):154-8. PubMed ID: 9740292
    [Abstract] [Full Text] [Related]

  • 35. Drug unresponsiveness & combination therapy for kala-azar.
    Jha TK.
    Indian J Med Res; 2006 Mar; 123(3):389-98. PubMed ID: 16778318
    [Abstract] [Full Text] [Related]

  • 36. Leishmania donovani: effect of verapamil on in vitro susceptibility of promastigote and amastigote stages of Indian clinical isolates to sodium stibogluconate.
    Valiathan R, Dubey ML, Mahajan RC, Malla N.
    Exp Parasitol; 2006 Oct; 114(2):103-8. PubMed ID: 16616137
    [Abstract] [Full Text] [Related]

  • 37. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries.
    Berman JD, Badaro R, Thakur CP, Wasunna KM, Behbehani K, Davidson R, Kuzoe F, Pang L, Weerasuriya K, Bryceson AD.
    Bull World Health Organ; 1998 Oct; 76(1):25-32. PubMed ID: 9615494
    [Abstract] [Full Text] [Related]

  • 38. Post-kala-azar dermal leishmaniasis (PKDL) developing after treatment of visceral leishmaniasis with amphotericin B and miltefosine.
    Kumar D, Ramesh V, Verma S, Ramam M, Salotra P.
    Ann Trop Med Parasitol; 2009 Dec; 103(8):727-30. PubMed ID: 20030997
    [No Abstract] [Full Text] [Related]

  • 39. Leishmania donovani: assessment of leishmanicidal effects of herbal extracts obtained from plants in the visceral leishmaniasis endemic area of Bihar, India.
    Singh SK, Bimal S, Narayan S, Jee C, Bimal D, Das P, Bimal R.
    Exp Parasitol; 2011 Feb; 127(2):552-8. PubMed ID: 21070771
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 31.